Dr. Simpson Highlights Potentially Remittive Anti-OX40s at Maui Derm

Two anti-OX40 drugs in the pipeline may have remittive properties for atopic dermatitis, according to Eric Simpson, MD.

Dr. Simpson moderated “Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025” at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.

During his own presentation as part of the panel, Dr. Simpson discussed various biologics for atopic dermatitis and the latest research surrounding them, and he closed with a preview of amlitelimab and rocatinlimab.

“These are costimulatory molecule pathways and may have remittive properties,” Dr. Simpson said.

Dr. Simpson showed preliminary data indicating that Q4W 100- and 250- mg doses of amlitelimab resulted in 59% and 52% of patients achieving EASI 75 through Week 16,¹ and >50% of patients on various dosages of rocatinlimab achieving EASI 75 through 36 weeks.²

“These are the phase 2 data that are close to the other biologics,” Dr. Simpson said. “We’ll be talking about these in the next couple years once we get some official phase 3 peer-reviewed data out.”

1. Weidinger S. A phase 2a study of KY1005, a novel non-depleting anti-OX40 ligand (OX40L) mAb in patients with moderate to severe AD. D1T01.3A, EADV Congress 2021, 29 Sept–2 Oct.
2. Guttman-Yassky E, et al. Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Arch Dermatol Res. 2024;316(10):747. doi: 10.1007/s00403-024-03426-x.